CoChat

Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?

The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.

Abstract

Diabetes mellitus is a major issue of public health, affecting more than 300 million people worldwide. Inhibitors of the sodium-glucose cotransporter-2 (SGLT-2) in the renal proximal tubule are a novel class of agents for the treatment of type 2 diabetes mellitus. Inhibition of the SGLT-2 results in reduced glucose reabsorption and improvement in glycemic control. Alongside glucose excretion, SGLT-2 inhibitors also have mild natriuretic and diuretic effects, combining actions of a proximal tubule diuretic and an osmotic diuretic; these properties are expected to lead to small blood pressure (BP) reductions. Clinical studies with dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin used either as monotherapy or add-on therapy and compared with placebo or active treatment have also examined the effect of these agents on BP as a secondary endpoint. Although with some differences between individual agents, all of the approved SGLT-2 inhibitors provided a mild but meaningful reduction in office SBP and DBP. Recent studies with the use of ambulatory blood pressure monitoring suggest that the magnitude of this BP reduction can be even greater. The aim of this review is to systematically summarize and present the studies reporting the effect of approved SGLT-2 inhibitors on BP.

Overview

Integrity signals

Registry

Crossref · 10.1097/hjh.0000000000000719

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 99 references

Research works printed but not linked: 5

  1. Weber, 2013, Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker., Circulation, 128, A13144
  2. Weber, 2013, Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen., Circulation, 128, A13165
  3. Inagaki, 2013, Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients., Diabetologia, 56, S82
  4. Haneda, 2013, Luseogliflozin, a SGLT2 inhibitor, as add-on therapy to 5 types of oral antidiabetic drugs improves glycaemic control and reduces body weight in Japanese patients with type 2 diabetes mellitus., Diabetologia, 56, S384
  5. Ikeda, 2012, A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus., Diabetologia, 55, S1

Cited by

See all 80

Metadata

Authors
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I.
Affiliations
Aristotle University of Thessaloniki (GR)
Corresponding author
Sarafidis, Pantelis A.
Venue
Journal of Hypertension
Published
2015-11
Volume
33
Issue
11
Pages
2185-2197
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2398685869
Cited by
71
References
100
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 5 · 2017: 9 · 2016: 7 · 2015: 1
FWCI
1.10
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
SGLT2 inhibitors, blood pressure reduction, type 2 diabetes, dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, tofogliflozin, sodium excretion, diuretic effect, ambulatory blood pressure monitoring, glycemic control
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents, Blood Pressure Monitoring, Ambulatory, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? https://app.cochat.ai/papers/10.1097/hjh.0000000000000719
The paper
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015). Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000000719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.